Ticagrelor
As of the edition of 20 October 2026, Ticagrelor is a small molecule: marketed, first approved in 2010 (EU); acts on P2RY12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Brilinta
- First approved
- 3 December 2010 (EU)
- Approvals on record
- 10 in 7 regions
- Holder of the most recent approval
- Pharos Pharmaceutical Oriented Services Ltd.; 3 holders in all
- Withdrawn from market
- 27 March 2013 (in some regions)
- Registered trials
- 302, 25 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Ticagrelor.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | Q9H244 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 53 | 27 | 9 | 1 |
| Phase 1 | 27 | 26 | 1 | 0 |
| Phase 2 | 25 | 19 | 0 | 2 |
| Phase 3 | 68 | 38 | 9 | 11 |
| Phase 4 | 129 | 74 | 14 | 11 |
| All trials | 302 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| AstraZeneca | Applicant and Lead sponsor of trials | 2006 to now |